Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. We set out to evaluate symptom burden and QOL in patients with advan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Mamoor, Maha, Postow, Michael A, Lavery, Jessica A, Baxi, Shrujal S, Khan, Niloufer, Mao, Jun J, Rogak, Lauren J, Sidlow, Robert, Thom, Bridgette, Wolchok, Jedd A, Korenstein, Deborah
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7061889/
https://ncbi.nlm.nih.gov/pubmed/32152222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados